Recruiting
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.
ClinicalTrials.gov IDNCT06273072
PhasePHASE2
Enrollment100
SponsorJohns Hopkins University
Age18 Years
SexALL
Conditions studied
Asthma, Asthma Chronic, Overweight and Obesity
About this study
This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.
Interventions
- Drug: Metformin hydrochloride extended-release tablets — titrated to 2000 mg once daily
- Drug: Visually identical placebo Metformin hydrochloride extended-release tablets — placebo
Primary outcomes
- Number of completed telemedicine visits (Baseline to week 24)
- Adherence to study drug (Baseline to week 24)
- Retention rate (Baseline to week 24)
Eligibility information
Inclusion Criteria:
* Physician-diagnosed asthma on maintenance therapy
* Not well-controlled asthma (ACT score \<20, or at least one asthma exacerbation requiring corticosteroids in the prior 12 months)
* Overweight or obesity: Body mass index ≥25kg/m2
* Adult: Age ≥18
Exclusion Criteria:
* Currently pregnant, expect to become pregnant in the next 6 months or are currently breastfeeding
* Major cardiovascular disease: heart failure, heart attack or stroke within the last 6 months
* Other chronic lung disease, inclusive of chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, pulmonary fibrosis
* Active smoking or former smoker with ≥20 pack-year smoking history
* Chronic kidney disease: estimated glomerular filtration rate ≤60 mL/min/1.73 m2
* Heavy alcohol use: in a typical week, 8 or more drinks for a woman or 15 or more drinks for a man
* Liver disease: elevation in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2x the upper limit of normal or prior diagnosis of liver disease
* Anemia: hemoglobin \< 13 g/dl in males and hemoglobin \< 11 g/dl in females
* Taking Glucagon Like Peptide 1(GLP-1) medications for weight loss
* Diabetes (Hemoglobin A1C ≥ 6.5% or taking metformin or other medications used to treat diabetes)
* Participation in any other clinical trial (observational studies are permitted)
Study locations
- Johns Hopkins University, Baltimore, Maryland 21224 United States
- Baylor College of Medicine, Houston, Texas 77030 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.